This is a repository copy of *Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are They Sensitive to Both Joint and Skin Aspects? [abstract]*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/91603/

Version: Accepted Version

**Proceedings Paper:**

https://doi.org/10.1002/art.39448

---

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are they Sensitive to Both Joint and Skin Aspects?

Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Amit Chhabra⁴, Heather Jones⁵ and Philip S. Helliwell⁶

¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

Background/Purpose
Psoriatic Arthritis Quality of Life (PsAQoL), Ankylosing Spondylitis Quality of Life (ASQoL), and Dermatology Life Quality Index (DLQI) are tools that assess different aspects of health-related quality of life (HRQoL) in psoriatic arthritis (PsA). We aimed to determine if each of the three tools capture HRQoL domains relevant to both skin and joints.

Methods
Patients with PsA (physician diagnosed) completed PsAQoL, ASQoL, and DLQI in a 15-country longitudinal study [1] designed to develop new composite measure for PsA. We used Rasch analysis to determine the reliability and validity, including how well the tools targeted the skin and joint aspects of HRQoL.

We assessed the following: (i) fit to the Rasch model to determine different aspects of validity in PsA, (ii) person-separation index to determine internal consistency, (iii) differential item functioning (DIF) across five regions (Asia, Europe, N. America, S. America and the UK) to determine cross-cultural validity, and (iv) person-item threshold location maps to determine targeting of the tools to skin and joint aspects of HRQoL.

Results
The sample comprised 503 patients (male/female = 286/217) with mean (SD) age, 50.8 (13.1), and PSA duration, 9.8 (9.9) years.

Expectations of the Rasch model were satisfied only in N America PsAQoL, UK ASQoL and both UK & N America DLQI datasets. Reliability was adequate and the measures were invariant to age and gender. There were not enough data in each country to reliably determine cross-cultural invariance, therefore targeting and discrimination properties of the tools were based on N. American dataset (Fig 1).

DLQI targeted better (than PsAQoL) articular and skin aspects of HRQoL. DLQI discriminated better HRQoL related to skin involvement (fig 1B and 1F) but not spinal involvement (fig 1D), where ASQoL was better at discriminating this aspect (F(1,66) = 13.76, p<0.001).

Conclusions
The data suggest that PsAQoL does not cover the full spectrum of HRQoL in psoriasis. Conversely, DLQI does not cover the full spectrum of HRQoL of articular disease in PsA. PsAQoL, (or ASQoL) and DLQI complement each other in capturing both joint and skin aspects of HRQoL. This needs to be demonstrated in a larger dataset.
Figure 1. Targeting and discriminating properties

Blue plots represent low scores and red plots high scores. Significant ANOVA p-values suggest ability of the tool to discriminate between persons with low/high disease. Green circles mark persons with severe HRQoL not targeted by PsAQoL items.

References